CNCE NASDAQ
Concert Pharmaceuticals, Inc.
1W: -0.1%
1M: -0.2%
3M: +73.7%
1Y: +171.8%
3Y: -12.0%
5Y: -60.2%
$8.37
Last traded 2023-03-03 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range2.72-8.55
Volume0
Avg Volume2,635,844
Beta0.52
Dividend—
Analyst Ratings
Company Info
CEORoger D. Tung
Employees64
SectorHealthcare
IndustryBiotechnology
IPO Date2014-02-13
Websiteconcertpharma.com
65 Hayden Avenue
Lexington, MA 02421
US
Lexington, MA 02421
US
781 860 0045
About Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc. functions as a biopharmaceutical firm in the clinical development phase, concentrating on the creation of innovative small-molecule therapeutics designed to address autoimmune conditions. Its primary investigational drug, CTP-543, is currently progressing through late-stage (Phase III) clinical trials for the treatment of alopecia areata, a serious autoimmune dermatological ailment. The company maintains strategic alliances with several partners, including Avanir Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., Cipla Technologies, and Processa Pharmaceuticals. Established in 2006, the organization's corporate headquarters are situated in Lexington, Massachusetts.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| van Heek Christi | U-Tender | 25,651 | $8.00 | 2023-03-06 |
| van Heek Christi | D-Return | 14,144 | $9.16 | 2023-03-06 |
| van Heek Christi | D-Return | 16,400 | — | 2023-03-06 |
| van Heek Christi | D-Return | 25,000 | $12.96 | 2023-03-06 |
| van Heek Christi | D-Return | 10,250 | $4.26 | 2023-03-06 |